@article{lelong:hal-04222881,
TITLE = {The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics},
AUTHOR = {Lelong, Margaux and Josien, R{\'e}gis and Coste-Burel, Marianne and Rimbert, Marie and Bressollette-Bodin, C{\'e}line and Nancey, St{\'e}phane and Bouguen, Guillaume and Allez, Matthieu and Serrero, M{\'e}lanie and Caillo, Ludovic and Rouillon, Cl{\'e}a and Blanc, Pierre and Laharie, David and Olivier, Rapha{\"e}l and Peyrin-Biroulet, Laurent and Dib, Nina and de Maissin, Astrid and Montuclard, C{\'e}line and Trang-Poisson, Caroline and Vavasseur, Fabienne and Gallot, G{\'e}raldine and Berthome, Mathilde and Braudeau, C{\'e}cile and Chevreuil, Justine and Bourreille, Arnaud and Le Berre, Catherine},
URL = {https://hal.science/hal-04222881},
JOURNAL = {Frontiers in Immunology},
PUBLISHER = {Frontiers},
VOLUME = {14},
PAGES = {1243898},
YEAR = {2023},
MONTH = Aug, DOI = {10.3389/fimmu.2023.1243898},
KEYWORDS = {Crohn's disease ; SARS-CoV-2 ; infliximab ; trough levels ; ulcerative colitis ; vedolizumab},
HAL_ID = {hal-04222881},
HAL_VERSION = {v1},
}